Stock listing

Xetra:87E Dianthus Therapeutics, Inc. Aktie

German listing (Xetra) of Dianthus Therapeutics, Inc. · home listing NASDAQ:DNTH

Follow Dianthus Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:DNTH

$84.55 USD +0.57 (+0.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DNTH

Past year +109.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$82.58 – $85.67 USDNov 20, 2026
Volume
784,842 sharesNov 20, 2026
Market cap
$4.76B USDAt the close on Nov 20, 2026 · price × 56.31M shares outstanding
52-week range
$35.84 – $117.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$75.93M USDMedian day 735,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Dianthus Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DNTH · Home$84.55 USD+0.57 (+0.7%)784,842$83.62$85.67$82.58$83.98Close on Nov 20, 2026
Frankfurt:87E€75.50 EUR-2.50 (-3.2%)—€75.50€75.50€75.50€78.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DNTH · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$84.55+0.57+0.7%$83.62$85.67$82.58784,842
$83.98-3.00-3.4%$86.84$89.00$83.62841,863
$86.98-2.57-2.9%$89.55$90.50$85.43553,443
$89.55-2.26-2.5%$90.29$93.81$87.85558,201
$91.81-0.67-0.7%$91.87$92.34$88.61681,514
$92.48+3.18+3.6%$88.12$92.79$83.84921,000
$89.30+0.49+0.6%$89.05$90.46$87.97735,021
$88.81-1.19-1.3%$89.86$90.48$86.92511,693
$90.00+3.97+4.6%$87.81$91.82$84.41700,293
$86.03+3.02+3.6%$84.12$87.44$82.13593,975
$83.01-2.80-3.3%$85.87$85.87$80.341,058,517
$85.81+3.11+3.8%$85.92$85.92$82.211,679,408
$82.70+0.45+0.5%$83.21$86.17$81.911,525,974
$82.25-0.13-0.2%$83.66$84.56$80.75837,698
$82.38-0.32-0.4%$81.29$83.73$80.63496,892
$82.70+0.39+0.5%$82.87$84.70$81.88849,055
$82.31+2.79+3.5%$77.82$82.45$77.26656,237
$79.52+0.19+0.2%$79.55$81.10$78.64748,687
$79.33+2.55+3.3%$77.87$79.90$77.12501,031
$76.78-1.75-2.2%$76.03$78.16$76.02379,227
$78.53+0.43+0.6%$77.13$78.96$75.401,480,230
$78.10-0.65-0.8%$78.89$80.74$77.261,194,116
$78.75+4.21+5.6%$74.61$79.93$73.171,865,288
$74.54+2.45+3.4%$73.55$76.04$72.13972,522
$72.09-2.44-3.3%$74.41$75.34$69.431,053,300
$74.53-0.23-0.3%$75.77$77.55$72.67943,600
$74.76-2.82-3.6%$77.17$78.78$74.47977,300
$77.58-3.99-4.9%$81.42$81.46$77.251,315,400
$81.57-0.80-1.0%$81.77$83.77$80.91853,900
$82.37-0.06-0.1%$82.36$85.20$82.13738,900
$82.43-2.45-2.9%$84.73$84.85$81.061,003,700
$84.88-0.52-0.6%$84.60$86.61$84.13562,500
$85.40-2.64-3.0%$88.58$88.58$83.191,347,600
$88.04-0.17-0.2%$88.44$89.58$86.09597,400
$88.21-0.11-0.1%$89.05$91.24$87.73751,400
$88.32+0.27+0.3%$88.40$91.04$87.22767,000
$88.05+0.89+1.0%$88.19$90.71$87.581,030,800
$87.16-0.67-0.8%$87.40$87.69$84.721,033,900
$87.83-0.72-0.8%$88.03$89.14$87.04652,700
$88.55-2.16-2.4%$91.56$92.89$88.34522,700
$90.71-2.73-2.9%$93.75$94.95$90.36726,200
$93.44-4.91-5.0%$98.35$98.53$89.781,187,400
$98.35+1.88+1.9%$96.84$100.47$96.551,124,800
$96.47-0.34-0.4%$95.95$99.67$94.58933,200
$96.81-4.31-4.3%$101.12$104.55$96.472,829,300
$101.12-1.37-1.3%$104.58$105.85$99.921,140,600
$102.49-2.28-2.2%$105.43$107.00$101.601,035,500
$104.77-2.92-2.7%$107.85$108.26$104.04479,000
$107.69+1.49+1.4%$108.36$109.76$106.55651,500
$106.20+2.92+2.8%$106.78$109.79$105.00732,800
$103.28-3.76-3.5%$105.88$107.64$101.60535,800
$107.04-2.09-1.9%$108.03$110.24$105.951,033,900
$109.13+1.03+1.0%$105.61$111.11$104.95631,100
$108.10+0.25+0.2%$107.06$109.61$105.65638,500
$107.85+1.61+1.5%$106.44$109.23$105.57355,700
$106.24-0.38-0.4%$107.69$110.44$103.13565,400
$106.62+1.01+1.0%$105.34$107.52$103.80576,600
$105.61-0.23-0.2%$105.33$107.20$102.38459,400
$105.84-5.70-5.1%$111.31$111.31$105.60376,200
$111.54+0.78+0.7%$111.28$112.13$109.69601,200
$110.76-1.35-1.2%$111.44$111.56$109.54335,400
$112.11+2.04+1.9%$112.23$113.86$110.20552,000
$110.07-1.03-0.9%$110.08$111.81$105.05531,900
$111.10+1.59+1.5%$110.30$112.72$108.95730,900
$109.51-4.19-3.7%$111.73$112.82$107.36735,500

Splits

1 split · NASDAQ:DNTH · every price before a split is adjusted for it

DayRatioWhat
1-for-16Consolidation
Ticker
Xetra:87E
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Xetra
Currency
EUR

What changed lately

Latest news

All Dianthus Therapeutics, Inc. news

Dianthus Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 132 in all · newest Nov 4, 2026 · oldest 2019
Decks
18 decks · latest August 2026

Where Dianthus Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DNTH · Home listingNASDAQUnited StatesUSD
gettex:87EgettexGermanyEUR
Tradegate:87ETradegateGermanyEUR
LS Exchange:A3ERZ4LS ExchangeGermanyEUR
Lang & Schwarz:A3ERZ4Lang & SchwarzGermanyEUR
BOATS:DNTHBOATSUnited StatesUSD
Dusseldorf:87EDusseldorfGermanyEUR
Frankfurt:87EFrankfurtGermanyEUR
Munich:87EMunichGermanyEUR
Stuttgart:87EStuttgartGermanyEUR
Xetra:87E · This pageXetraGermanyEUR

Valuation

EV/sales 1,444× against a median of 5.7×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$3.92B USD
P/E
Loss
EV/sales
1,444×
EV/EBITDA
Negative EBITDA
Price/book
3.8×
Gross margin
97.2%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
0.90

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Dianthus Therapeutics, Inc. · NASDAQ:DNTHUS$4.76BUS$3.92Bn/a1,444×n/a3.8×n/a0.0×0.90
Belite Bio, Inc. · NASDAQ:BLTEUS$5.13BUS$5.13Bn/an/an/a6.6×n/a0.0×1.34
SK Biopharmaceuticals Co., Ltd. · KRX:326030US$5.05BUS$4.77B16.9×7.5×20.1×6.7×46.6%0.0×n/a
Veradermics, Incorporated · NYSE:MANEUS$5.04BUS$4.25Bn/an/an/a6.3×n/a0.0×1.13
Liquidia Corporation · NASDAQ:LQDAUS$4.90BUS$4.68Bn/a7.5×n/an/a−15.2%n/a0.84
Erasca, Inc. · NASDAQ:ERASUS$4.78BUS$4.18Bn/an/an/a5.2×n/a0.1×1.51
PTC Therapeutics, Inc. · NASDAQ:PTCTUS$4.71BUS$3.12Bn/a2.7×n/an/a−9.2%n/a0.88
Cogent Biosciences, Inc. · NASDAQ:COGTUS$4.65BUS$4.08Bn/an/an/a9.0×n/a0.4×1.30
Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSAUS$4.53BUS$3.97B41.4×4.2×29.9×6.4×11.6%0.0×0.57
Travere Therapeutics, Inc. · NASDAQ:TVTXUS$4.51BUS$4.21Bn/a6.5×n/a200×−18.7%0.0×1.31
Ionis Pharmaceuticals, Inc. · NASDAQ:IONSUS$4.43BUS$4.70Bn/a4.9×n/a11.3×−56.9%5.5×0.40
Median of the othersUS$4.75BUS$4.23B29.2×5.7×25.0×6.6×−12.2%0.0×1.13

Forecasts

17 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
139.25 USD · Analysts' mean
EPS, year to Dec 2026
-3.56 · 10 analysts
Revenue, year to Dec 2026
2.6M · 14 analysts

Team and board

Officers

OfficerRole
Marino GarciaPresident & Chief Executive Officer, Board Member
Ryan SavitzExecutive Vice President, Chief Financial Officer & Chief Business Officer
Adam VenessGeneral Counsel
Jennifer Davis RuffHead of Investor Relations and Corporate Affairs
Jennifer CrossVP, Pipeline Strategy & Research
Simrat RandhawaExecutive Vice President, Head of R&D
Edward CarrChief Accounting Officer
Judson TaylorHead of Technical Operations
Kristina MaximenkoChief People Officer
Polly HanffHead of Quality
Rivka GluckHead of Clinical Development Operations
Ronny HashmonayChief Development and Medical Affairs Officer
Scott NogiHead of Business Operations
Sue EvansHead of Regulatory Affairs

Board

DirectorRole
Marino GarciaPresident & Chief Executive Officer, Board Member

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−3.3%
Q2 2026Aug 4, 2026 · After close+1.9%
Q1 2026May 5, 2026 · After close+0.2%
Q4 2025Mar 9, 2026+33.3%
Q3 2025Nov 5, 2025 · After close+8.0%
Q2 2025Aug 7, 2025 · After close−2.0%
Q1 2025May 12, 2025 · After close−6.2%
Q4 2024Mar 19, 2025 · Before open−0.7%
Q3 2024Nov 7, 2024 · After close−2.8%
Q2 2024Aug 8, 2024 · After close+2.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−2.6%
Q4 2023Mar 21, 2024 · After close+14.3%
Q3 2023Nov 9, 2023 · After close+0.8%
Q2 2023Sep 18, 2023+1.1%
Q1 2023May 11, 2023−10.7%
Q4 2022Mar 7, 2023−1.9%
Q3 2022Nov 3, 2022−2.4%
Q2 2022Aug 4, 2022+14.7%
Q1 2022May 16, 2022+3.5%
Q4 2021Mar 8, 2022+14.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck97 slidesAugust 2026
Investor Presentation (June 2026)Investor deck94 slidesJun 12, 2026
Investor Presentation (March 2026)Investor deck84 slidesMar 26, 2026
Corporate Update (March 2026)Corporate update22 slidesMar 9, 2026
44th Annual J.P. Morgan Healthcare Conference (January 2026)Conference29 slidesJan 12, 2026
Investor Presentation (January 2026)Investor deck74 slidesJan 12, 2026
Investor Presentation (November 2025)Investor deck72 slidesNov 3, 2025
Merger or Acquisition (October 2025)Merger or acquisition19 slidesOct 16, 2025
Investor Presentation (September 2025)Investor deck32 slidesSep 8, 2025
Virtual Industry Forum (2025)Conference27 slides2025
All 18 decks
DeckKindSlidesDate
Investor Presentation (December 2024)Investor deck31 slidesDec 12, 2024
Investor Presentation (June 2024)Investor deck27 slidesJun 6, 2024
Investor Presentation (January 2024)Investor deck25 slidesJan 8, 2024
Magenta Therapeutics — Merger or Acquisition (August 2023)Merger or acquisition22 slidesAug 31, 2023
Magenta Therapeutics — Merger or Acquisition (May 2023)Merger or acquisition28 slidesMay 3, 2023
Magenta Therapeutics — ASH Annual Meeting 2022Conference31 slidesDec 13, 2022
Magenta Therapeutics — Investor Presentation (January 2020)Investor deck43 slidesJan 13, 2020
Magenta Therapeutics — Investor Presentation (January 2019)Investor deck40 slidesJan 7, 2019

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$288M raised · US$33 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Stifel (co-lead), LifeSci Capital
Use of proceeds: Advance preclinical and clinical development activities, working capital and general corporate purposes
Sep 11, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Magenta Therapeutics, Inc. Priced at US$15.00 a share on Jun 20, 2018.

Price
US$15.00 a share
Shares offered
6,666,667 shares of common stock
Offering size
US$100 million
Underwriters' option
Up to 1,000,000 more shares
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Wedbush PacGrow · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 28, 2018
Filed publiclyMay 24, 2018
Amended 3 timesNewest Jun 19, 2018
Shares registered with an exchangeJun 19, 2018
Declared effective by the SECJun 20, 2018
Final prospectus, with the priceJun 21, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.04M6.24M2.83M6.42M1.48M0000
Cost of revenue412.0K355.0K147.0K2.02M1.98M1.84M875.0K376.0K6.00K
Gross profit2.04M6.24M2.83M6.42M1.48M-1.98M-1.84M-875.0K-376.0K-6.00K
Research and development145.6M83.1M32.8M29.4M46.8M50.6M59.2M41.3M27.9M5.78M
Selling, general and administrative34.3M25.0M18.2M6.74M1.96M28.1M23.8M18.6M7.83M3.49M
Operating income-177.9M-101.9M-48.2M-29.7M-74.7M-78.7M-83.0M-60.0M-35.7M-9.27M
Depreciation and amortization111.0K96.0K67.0K1.93M2.02M1.98M1.84M875.0K376.0K6.00K
EBITDA-177.8M-101.8M-48.1M-27.8M-72.7M-76.7M-81.1M-59.1M-35.4M-9.26M
Interest expense3.56M3.77M163.0K
Income before tax-162.3M-85.0M-43.6M-28.5M-13.1M-74.9M-76.8M-57.5M-35.5M-9.43M
Income tax0000000000
Net income-162.3M-85.0M-43.6M-28.5M-71.1M-74.9M-76.8M-57.5M-35.5M-9.43M
Earnings per share, basic-4.20-2.55-8.45-32.57-1.29-1.71-2.07-3.13-19.12-65.15
Earnings per share, diluted-4.20-2.55-8.45-32.57-1.29-1.71-2.07-3.13-19.12-65.15

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents51.1M22.8M132.3M15.4M131.7M58.2M65.1M58.3M51.4M4.51M
Short-term investments353.2M252.4M41.4M60.1M45.3M90.7M80.7M84.2M
Receivables52.0K0294.0K4.70M1.48M6.25M
Inventory852.0K264.0K
Current assets409.4M280.9M177.5M82.0M180.7M151.5M149.8M145.3M52.5M10.8M
Property, plant and equipment296.0K194.0K185.0K142.0K7.46M8.31M9.89M10.2M1.96M
Total assets530.9M374.0M179.4M83.1M189.9M161.6M161.5M157.3M54.5M11.3M
Accounts payable9.72M4.58M2.61M1.17M3.04M3.76M2.81M3.49M167.0K1.67M
Current liabilities30.7M18.5M9.63M8.22M10.9M11.4M14.1M10.4M4.14M2.30M
Total debt1.39M1.49M585.0K788.0K
Total liabilities37.5M21.5M10.5M9.45M17.3M17.7M20.3M11.7M4.14M2.30M
Shareholders' equity493.4M352.5M168.9M-44.4M-17.2M143.9M141.2M145.6M-42.1M-8.87M
Shares outstanding43.2M31.1M14.8M875.3K58.8M48.5M39.3M33.3M2.35M39.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-129.1M-78.2M-36.9M-29.1M-59.5M-64.0M-57.1M-41.9M-22.3M-6.53M
Capital spending-213.0K-105.0K-110.0K-314.0K-1.26M-400.0K-3.06M-7.67M-2.20M-139.0K
Free cash flow-129.3M-78.3M-37.0M-29.4M-60.8M-64.4M-60.2M-49.6M-24.5M-6.67M
Cash from investing-122.8M-286.8M20.3M-59.8M43.4M-10.6M1.53M-91.7M-2.20M-139.0K
Cash from financing280.1M255.6M133.6M96.7M89.6M67.7M62.3M142.1M71.5M10.7M
Share buybacks317.0K-88.0K-213.0K-107.0K
Change in cash28.2M-109.4M117.0M7.79M73.5M-6.92M6.73M8.56M47.0M4.04M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
S-3ASR · Registration statementSep 18, 2026Offer documentSEC
144 · Notice of proposed saleSep 17, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
144 · Notice of proposed saleAug 10, 2026Other filingsSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 28, 2026Big-stake noticeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
144 · Notice of proposed saleJun 17, 2026Other filingsSEC
8-K · Current reportJun 12, 2026Current reportSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
8-K · Current reportMay 22, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
4 · Change in ownershipApr 10, 2026Insider tradeSEC
144 · Notice of proposed saleApr 9, 2026Other filingsSEC
ARS · Annual report to shareholdersApr 9, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 9, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2026Meeting noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
144 · Notice of proposed saleMar 31, 2026Other filingsSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
8-K · Current reportMar 26, 2026Current reportSEC
144 · Notice of proposed saleMar 24, 2026Other filingsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
8-K · Current reportMar 12, 2026Material contractSEC
424B5 · ProspectusMar 11, 2026Offer documentSEC
S-3MEFMar 10, 2026Other filingsSEC
424B5 · ProspectusMar 9, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 29, 2026Other filingsSEC
S-3 · Registration statementJan 28, 2026Offer documentSEC
8-K · Current reportJan 12, 2026ResultsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 25, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 19, 2025Big-stake noticeSEC
4 · Change in ownershipNov 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K · Current reportNov 3, 2025Current reportSEC
8-K · Current reportOct 16, 2025ResultsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipSep 25, 2025Insider tradeSEC
4 · Change in ownershipSep 25, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 12, 2025Big-stake noticeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
8-K · Current reportSep 11, 2025Material contractSEC
424B5 · ProspectusSep 10, 2025Offer documentSEC
144 · Notice of proposed saleSep 9, 2025Other filingsSEC
424B5 · ProspectusSep 8, 2025Offer documentSEC
8-K · Current reportSep 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 22, 2025Insider tradeSEC
8-K · Current reportMay 22, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 17, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 10, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 10, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 10, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMar 24, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 19, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportMar 5, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportDec 12, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedDec 3, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 22, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
RW · Request to withdraw a registrationOct 21, 2024Other filingsSEC
424B5 · ProspectusOct 11, 2024Offer documentSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
424B3 · ProspectusOct 11, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 10, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveOct 10, 2024Other filingsSEC
CORRESP · Letter to the SECOct 7, 2024Other filingsSEC
CORRESP · Letter to the SECOct 7, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 7, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 7, 2024Other filingsSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
S-3 · Registration statementOct 1, 2024Offer documentSEC
S-3 · Registration statementOct 1, 2024Offer documentSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
424B3 · ProspectusSep 16, 2024Offer documentSEC
8-K · Current reportSep 16, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedSep 12, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 8, 2024Offer documentSEC
424B3 · ProspectusAug 8, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJun 6, 2024Current reportSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC

This page holds 200 of 661 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Dianthus Therapeutics, Inc.’s releases · as of Nov 2, 2026

Common shares
56,312,712
Fully diluted
56,312,712

Fully diluted

LineSharesAs of
Common shares56,312,712Nov 2, 2026

Share count over time

CountShares
Nov 2, 202656,312,712

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Fidelity8.55MUS$753M+353KNov 10, 2026
T. Rowe Price8.09MUS$713M+1.69MNov 16, 2026
Vanguard4.44MUS$391M+1.35MNov 16, 2026
BlackRock4.39MUS$387M+266KNov 13, 2026
Wellington3.01MUS$265M−224KNov 16, 2026
Fairmount Funds Management LLC2.54MUS$223MNo changeNov 16, 2026
State Street2.53MUS$223M+177KNov 12, 2026
Avidity Partners Management LP1.9MUS$167M−205KNov 16, 2026
Octagon Capital Advisors LP1.69MUS$149M−155KNov 16, 2026
TCG Crossover Management, LLC1.68MUS$148MNo changeNov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Geode Capital1.42MUS$125M+165KNov 6, 2026
Fred Alger Management, LLC1.3MUS$115M−939Nov 16, 2026
UBS1.28MUS$112M+61,005Nov 16, 2026
Jennison Associates LLC1.15MUS$101M+130KNov 13, 2026
Franklin Templeton1.11MUS$95M+138KNov 12, 2026
Polar Capital Holdings Plc1.02MUS$89.4M−3,124Nov 16, 2026
Deerfield Management Company, L.P.914KUS$80.5M−211KNov 16, 2026
Baker Bros. Advisors LP852KUS$75MNo changeNov 16, 2026
Venrock Adviser, LLC822KUS$72.4M−358KNov 16, 2026
AllianceBernstein821KUS$72.3M−13,116Nov 16, 2026
Goldman Sachs775KUS$68.2M+393KNov 16, 2026
Assenagon Asset Management S.A.732KUS$64.5M+171KOct 15, 2026
Citadel629KUS$55.4M−346KNov 16, 2026
Braidwell LP518KUS$45.6M−76,164Nov 16, 2026
Schwab509KUS$44.8M+143KNov 16, 2026
Logos Global Management LP500KUS$44M−300KNov 19, 2026
Cormorant Asset Management, LP500KUS$44M−250KNov 16, 2026
Ameriprise491KUS$43.2M−41,359Nov 16, 2026
Westfield Capital Management Co LP474KUS$41.8M+159KNov 12, 2026
Bank of America465KUS$40.9M+208KNov 16, 2026
Pictet Asset Management Holding SA462KUS$40.7M+215KNov 3, 2026
Northern Trust444KUS$39.1M+31,757Nov 16, 2026
Barclays439KUS$38.7M+7,523Nov 6, 2026
Spruce Street Capital LP355KUS$31.2MNo changeNov 13, 2026
Affinity Asset Advisors, LLC350KUS$30.8M−50,000Nov 13, 2026
Woodline Partners LP301KUS$26.5M−200KNov 16, 2026
Lord, Abbett & Co. LLC296KUS$26.1M−126KNov 13, 2026
Driehaus Capital Management LLC296KUS$26M+548Nov 16, 2026
Point72 Asset Management, L.P.291KUS$25.6MNewNov 16, 2026
Fisher Asset Management, LLC273KUS$24M+250KNov 6, 2026
Tang Capital Management LLC265KUS$23.3MNo changeNov 16, 2026
BNY264KUS$23.2M+7,523Nov 5, 2026
Rtw Investments, LP248KUS$21.8MNo changeNov 16, 2026
Emerald Advisers, LLC247KUS$21.8M−319Nov 9, 2026
Dimensional243KUS$21.4M−78,548Nov 4, 2026
Silverarc Capital Management, LLC237KUS$20.8M−153KNov 12, 2026
LMR Partners LLP234KUS$20.6M+10,179Nov 16, 2026
Eventide Asset Management, LLC225KUS$19.8MNo changeNov 13, 2026
Millennium212KUS$18.6M+120KNov 16, 2026
TD205KUS$17.8M−20,706Nov 13, 2026

This page holds 50 of 267 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Vanguard Total Stock Market Index Fund1.65MUS$161M+84,454Jun 30, 2026
Fidelity Growth Company Fund1.59MUS$148M+410KMay 31, 2026
Vanguard Health Care Fund1.5MUS$161M+259KJul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.3MUS$127M+716KJun 30, 2026
iShares Russell 2000 ETF1.21MUS$118M+340KJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.1.16MUS$113M+656KJun 30, 2026
Fidelity Advisor Biotechnology Fund730KUS$78.1MNo changeJul 31, 2026
T. Rowe Price New Horizons Fund, Inc.673KUS$65.6M+484KJun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund625KUS$60.9M+351KJun 30, 2026
Fidelity Small Cap Index Fund517KUS$55.3M+163KJul 31, 2026
Show 50 holders
HolderSharesValueChangeAs of
T. Rowe Price Mid-Cap Growth Fund, Inc.515KUS$50.2MNewJun 30, 2026
Fidelity Small Cap Growth Fund468KUS$50.1MNo changeJul 31, 2026
Vanguard Extended Market Index Fund458KUS$44.6M+46,376Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund453KUS$44.2M+340KJun 30, 2026
iShares Russell 2000 Growth ETF444KUS$43.3M+419KJun 30, 2026
Fidelity Growth Company K6 Fund443KUS$41.2M+110KMay 31, 2026
T. Rowe Price Health Sciences Fund, Inc.429KUS$41.8M−54,000Jun 30, 2026
Select Biotechnology Portfolio421KUS$39.1M−11,700May 31, 2026
Fidelity Series Growth Company Fund407KUS$37.8M+82,119May 31, 2026
Alger Focus Equity Fund397KUS$42.5M+24,224Jul 31, 2026
Fidelity Stock Selector Small Cap Fund301KUS$32.2M−63,500Jul 31, 2026
Fidelity Series Small Cap Opportunities Fund289KUS$30.9M−45,900Jul 31, 2026
Franklin Biotechnology Discovery Fund250KUS$26.8M−20,491Jul 31, 2026
Alger Spectra Fund243KUS$26MNo changeJul 31, 2026
PGIM Jennison Small Company Fund239KUS$23.3MNewJun 30, 2026
Franklin Small Cap Growth Fund234KUS$25.1M+26,289Jul 31, 2026
Fidelity Small Cap Growth K6 Fund233KUS$24.9MNo changeJul 31, 2026
Vanguard Explorer Fund228KUS$24.3MNewJul 31, 2026
Eventide Healthcare & Life Sciences Fund225KUS$22MNo changeJun 30, 2026
Lord Abbett Developing Growth Fund Inc217KUS$23.2M+101KJul 31, 2026
Select Health Care Portfolio207KUS$19.3MNewMay 31, 2026
AB Small Cap Growth Portfolio202KUS$19.7M+9,493Jun 30, 2026
Columbia Small Cap Growth Fund193KUS$18M+52,466May 31, 2026
PGIM Jennison Health Sciences Fund191KUS$17.7MNewMay 29, 2026
Fidelity Extended Market Index Fund191KUS$17.7M+35,873May 31, 2026
BlackRock Health Sciences Opportunities Portfolio186KUS$17.3M+78,449May 29, 2026
Vanguard Russell 2000 Index Fund184KUS$17.1M+62,947May 31, 2026
Schwab U.S. Small-Cap ETF178KUS$16.6M+33,480May 31, 2026
AB Discovery Growth Fund, Inc.169KUS$16.5M−8,348Jun 30, 2026
Fidelity Advisor Health Care Fund163KUS$17.5M+78,257Jul 31, 2026
Artisan International Small-Mid Fund158KUS$15.4M−79,985Jun 30, 2026
Harbor Small Cap Growth Fund157KUS$16.8MNewJul 31, 2026
Fidelity Balanced Fund137KUS$12.7MNewMay 31, 2026
SmallCap Growth Fund I131KUS$14M+55,664Jul 31, 2026
Alger Capital Appreciation Institutional Fund126KUS$13.4MNo changeJul 31, 2026
T. Rowe Price Small-Cap Value Fund, Inc.122KUS$11.9M+26,824Jun 30, 2026
Schwab Small-Cap Index Fund115KUS$12.3M+36,383Jul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund113KUS$12.1MNewJul 31, 2026
Vanguard Health Care Index Fund105KUS$9.75M+56,964May 31, 2026
Alger Capital Appreciation Fund91,426US$9.78M+12,636Jul 31, 2026

This page holds 50 of 315 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Savitz Ryan
Officer: EVP, CFO & CBO
Sale17,724USD 90.56US$1.61MNov 12, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale3,044USD 90.03US$274KNov 11, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale2,561USD 90.14US$231KNov 10, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale2,064USD 91.59US$189KNov 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale300USD 85.16US$25,548Nov 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale700USD 86.70US$60,690Nov 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale1,736USD 88.84US$154KNov 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale37,517USD 90.12US$3.38MNov 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale58,396USD 90.90US$5.31MNov 9, 2026
Carr Edward
Officer: CHIEF ACCOUNTING OFFICER
Sale7,928USD 100.43US$796KSep 17, 2026
Show 50 trades
InsiderTradeSharesPriceValueDate
Carr Edward
Officer: CHIEF ACCOUNTING OFFICER
Sale6,771USD 101.37US$686KSep 17, 2026
Carr Edward
Officer: CHIEF ACCOUNTING OFFICER
Sale3,501USD 102.39US$358KSep 17, 2026
Carr Edward
Officer: CHIEF ACCOUNTING OFFICER
Sale1,100USD 103.20US$114KSep 17, 2026
Carr Edward
Officer: CHIEF ACCOUNTING OFFICER
Sale700USD 104.39US$73,073Sep 17, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale2,600USD 105.19US$273KSep 1, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale7,215USD 106.25US$767KSep 1, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale13,309USD 106.74US$1.42MSep 1, 2026
Read Simon
Director
Sale2,778USD 117.55US$327KAug 19, 2026
Read Simon
Director
Sale70USD 107.11US$7,498Aug 10, 2026
Read Simon
Director
Sale737USD 108.17US$79,721Aug 10, 2026
Read Simon
Director
Sale831USD 108.95US$90,537Aug 10, 2026
Read Simon
Director
Sale272USD 109.96US$29,909Aug 10, 2026
Read Simon
Director
Sale470USD 111.05US$52,194Aug 10, 2026
Read Simon
Director
Sale397USD 111.77US$44,373Aug 10, 2026
Veness Adam M
Officer: SVP, General Counsel and Sec.
Sale16,167USD 110.38US$1.78MAug 10, 2026
McGeorge Anne
Director
Sale1,450USD 107.58US$156KAug 10, 2026
McGeorge Anne
Director
Sale2,800USD 108.38US$303KAug 10, 2026
McGeorge Anne
Director
Sale1,800USD 109.30US$197KAug 10, 2026
McGeorge Anne
Director
Sale1,000USD 110.64US$111KAug 10, 2026
McGeorge Anne
Director
Sale700USD 111.41US$77,987Aug 10, 2026
Veness Adam M
Officer: SVP, General Counsel and Sec.
Sale3,217USD 110.61US$356KAug 7, 2026
Veness Adam M
Officer: SVP, General Counsel and Sec.
Sale616USD 111.18US$68,487Aug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale10,384USD 107.49US$1.12MAug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale23,907USD 108.05US$2.58MAug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale2,373USD 109.10US$259KAug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale2,536USD 110.02US$279KAug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale800USD 110.76US$88,608Aug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale104,091USD 107.96US$11.2MAug 7, 2026
Garcia Marino
Director, Officer: CEO AND PRESIDENT
Sale21,909USD 108.72US$2.38MAug 7, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale10,354USD 100.22US$1.04MJul 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale15,329USD 101.24US$1.55MJul 9, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale5,566USD 101.97US$568KJul 9, 2026
Veness Adam M
Officer: SVP, General Counsel and Sec.
Sale16,771USD 80.34US$1.35MJun 17, 2026
Veness Adam M
Officer: SVP, General Counsel and Sec.
Sale13,229USD 81.38US$1.08MJun 17, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale5,428USD 89.72US$487KJun 1, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale16,943USD 90.72US$1.54MJun 1, 2026
Randhawa Simrat
Officer: EVP, Head of R&D
Sale4,159USD 91.37US$380KJun 1, 2026
Soteropoulos Paula
Director
Sale599USD 85.47US$51,197May 8, 2026
Savitz Ryan
Officer: EVP, CFO & CBO
Sale8,224USD 89.84US$739KApr 9, 2026
Soteropoulos Paula
Director
Sale599USD 80.11US$47,986Mar 31, 2026

This page holds 50 of 58 trades. Open Shareholders

Big stakes

HolderStakeSharesDate
FMR LLC15.00%5.97MSep 30, 2025
T. Rowe Price Investment Management, Inc.10.50%5.89MSep 30, 2026
BlackRock, Inc.6.40%3.5MJun 30, 2026
Wellington Management Group LLP5.90%3.23MJun 30, 2026
Vanguard Capital Management LLC5.08%2.85MSep 30, 2026
Fairmount Funds Management LLC4.90%2.14MNov 21, 2025
Avidity Partners Management LP4.90%2.1MNov 17, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael W. Bonney
Other companies: Immunic, Inc. (Chair · Since May 16, 2026); Autolus Therapeutics plc (Director · Since at least Mar 18, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Dec 17, 2014); Bristol-Myers Squibb Company (Director · Nov 20, 2019 – Jun 30, 2021 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Jun 30, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 14, 2018 – Jun 11, 2019 · Past); Sarepta Therapeutics, Inc. (Director · Dec 4, 2017 – Feb 28, 2020 · Past); Global Blood Therapeutics Inc (Director · Feb 8, 2016 – Jun 16, 2016 · Past); Celgene Corporation (Director · Apr 14, 2015 – Nov 20, 2019 · Past); NPS Pharmaceuticals Inc (Director · Jan 17, 2006 – Feb 21, 2015 · Past); Cubist Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 3, 2006 – Jan 21, 2015 · Past)
Director · Jun 20, 2018 – Jun 1, 2021 · Past
Alexis Borisy
Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Tango Therapeutics, Inc. (Director · Since at least Aug 10, 2021); Relay Therapeutics, Inc. (Director · Since at least Jul 15, 2020); Revolution Medicines, Inc. (Director · Since at least Feb 12, 2020); Blueprint Medicines Corp (Director · Since at least Apr 30, 2015); OPKO Health, Inc. (Director · May 9, 2022 – Jun 22, 2023 · Past); EQRx Inc (Executive Chairman, Director · Dec 17, 2021 – Nov 9, 2023 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); EPIRUS Biopharmaceuticals Inc (CEO & President, Director · Jan 26, 2006 – Jan 26, 2009 · Past)
Director · Jun 20, 2018 – Aug 26, 2021 · Past
Peter Harwin
Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past)
Director · Sep 11, 2023 – Jan 22, 2024 · Past
Alison Frances Lawton
Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Spyre Therapeutics, Inc. (Director · Dec 15, 2020 – Jun 22, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Oct 5, 2020 – Jun 10, 2024 · Past); Kaleido Biosciences, Inc. (See Remarks, Director · Feb 27, 2019 – Apr 15, 2020 · Past); CoLucid Pharmaceuticals Inc (Director · Mar 11, 2016 – Mar 1, 2017 · Past); Tempest Therapeutics, Inc. (Chief Operating Officer · Jan 21, 2013 – Jun 7, 2013 · Past); Verastem, Inc. (Director · Nov 26, 2012 – Jun 21, 2019 · Past); Cubist Pharmaceuticals Inc (Director · Feb 15, 2012 – Jan 21, 2015 · Past)
Director · Since at least Dec 22, 2020
Tomas Kiselak
Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020)
Director · Sep 11, 2023 – Sep 27, 2024 · Past
Bruce Booth
Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Co-Founder · Since at least Aug 20, 2020); Tectonic Therapeutic, Inc. (Director · Jun 20, 2018 – Jun 6, 2023 · Past); Cogent Biosciences, Inc. (Director · Mar 28, 2018 – Jul 1, 2020 · Past); Viridian Therapeutics, Inc. (Director · Feb 13, 2017 – Jun 27, 2018 · Past); Larimar Therapeutics, Inc. (Director · Jun 18, 2014 – Jan 3, 2018 · Past)
Director · Jun 20, 2018 – Jun 28, 2022 · Past
Jonathan Violin
Other companies: Cyclerion Therapeutics, Inc. (Chief Executive Officer · Since at least Apr 1, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Viridian Therapeutics, Inc. (Chief Executive Officer, Director · Oct 27, 2020 – Feb 2, 2023 · Past); Trevena, Inc. (SVP-Scientific Affairs & IR · Jan 29, 2018 – Feb 28, 2018 · Past)
Director · Since at least Sep 11, 2023
Thomas Daniel
Other companies: Gossamer Bio, Inc. (Director · Since at least Feb 7, 2019); Larimar Therapeutics, Inc. (Director · Mar 3, 2016 – May 12, 2021 · Past); Juno Therapeutics Inc (Director · Aug 11, 2015 – Mar 5, 2018 · Past); Epizyme Inc (Director · May 30, 2013 – May 30, 2013 · Past); Celgene Corporation (see remarks · Feb 15, 2012 – Dec 31, 2015 · Past)
Director · Jun 20, 2018 – Jun 28, 2022 · Past
Leon O Moulder Jr
Other companies: Zenas BioPharma, Inc. (See Remarks, Director · Since at least Sep 12, 2024); Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Trevena, Inc. (Director · May 16, 2018 – Jun 15, 2023 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past)
Director · Sep 11, 2023 – May 23, 2024 · Past
Michael Vasconcelles
Other companies: Day One Biopharmaceuticals Inc (Head of Research and Dev. · Since at least Jun 16, 2025); Kura Oncology, Inc. (Director · Since at least Sep 13, 2024); ImmunoGen Inc (EVP R&D & MEDICAL AFFAIRS · Dec 29, 2022 – Feb 12, 2024 · Past); Cogent Biosciences, Inc. (Chief Medical Officer · Mar 28, 2018 – Mar 1, 2019 · Past)
Director · Aug 15, 2022 – Aug 15, 2022 · Past
All 41 people
PersonSeat
David Scadden
Other companies: Editas Medicine, Inc. (Director · Since at least Feb 5, 2019); Agios Pharmaceuticals, Inc. (Independent Director · Since at least May 27, 2017); Carisma Therapeutics, Inc. (Director · Jun 30, 2024 – Jul 1, 2024 · Past)
Director · Jun 20, 2018 – Jun 28, 2022 · Past
Jason Ryan
Other companies: GeneDx Holdings Corp. (Director · Since at least Jul 22, 2021); Singular Genomics Systems Inc (Director · May 26, 2021 – Feb 21, 2025 · Past); Foundation Medicine Inc (Chief Financial Officer · Sep 24, 2013 – Jul 31, 2018 · Past)
See Remarks · Jan 1, 2019 – Feb 10, 2020 · Past
Jeffrey Albers
Other companies: Spyre Therapeutics, Inc. (Director · Since at least Nov 22, 2023); Kymera Therapeutics, Inc. (Director · Since at least Aug 20, 2020); Blueprint Medicines Corp (Director · Since at least Apr 30, 2015)
Director · Jun 20, 2018 – Jun 28, 2022 · Past
Jeffrey Humphrey
Other companies: Lantheus Holdings, Inc. (Chief Medical Officer · May 28, 2024 – Jun 17, 2024 · Past); Cyteir Therapeutics Inc (Director · Dec 15, 2021 – Feb 3, 2023 · Past); Constellation Pharmaceuticals Inc (Chief Medical Officer · Jun 22, 2020 – Jul 15, 2021 · Past)
Chief Medical Officer · Oct 1, 2021 – Aug 1, 2022 · Past
Paula Soteropoulos
Other companies: Rallybio Corporation (Lead Independent Director · Since at least Jul 29, 2021); Akcea Therapeutics Inc (Chief Executive Officer, Director · Jul 13, 2017 – Sep 26, 2019 · Past); uniQure N.V. (Director · Jan 1, 2017 – Jun 13, 2024 · Past)
Director · Since at least Sep 11, 2023
Adam Veness
Other companies: Cyteir Therapeutics Inc (General Counsel · Apr 25, 2022 – Feb 3, 2023 · Past); Acceleron Pharma Inc (SVP, General Counsel and Sec. · Jun 5, 2019 – Nov 19, 2021 · Past)
General Counsel · Since at least Sep 11, 2023
Caren Deardorf
Other companies: Alpha Cognition Inc. (Director · Since Nov 9, 2026); Crinetics Pharmaceuticals, Inc. (Chief Business & Strategy Officer · Since at least Mar 11, 2022)
Chief Commercial Officer · Jul 6, 2021 – Nov 30, 2022 · Past
Marino Garcia
Other companies: AgomAb Therapeutics NV (Director · Since at least Sep 11, 2026); Synergy Pharmaceuticals Inc (EVP and Chief Strategy Officer · Jan 5, 2018 – Jan 5, 2018 · Past)
President & Chief Executive Officer, Board Member · Since at least Sep 11, 2023
Stephen F Mahoney
Other companies: Viridian Therapeutics, Inc. (President and CEO, Director · Since at least Oct 30, 2023); Kiniksa Pharmaceuticals International, plc (President & COO · May 23, 2018 – Sep 17, 2019 · Past)
See Remarks · Nov 2, 2020 – Nov 30, 2022 · Past
Steven J Romano
Other companies: Silence Therapeutics PLC (EVP and Chief R&D Officer · Since at least Jan 2, 2025); Mallinckrodt Inc (EVP & Chief Sci. Ofcr · May 4, 2015 – Jun 16, 2022 · Past)
Director · Since at least Sep 16, 2024
Sujay Kango
Other companies: Lite Strategy, Inc. (Director · Nov 22, 2021 – Sep 29, 2023 · Past); Acceleron Pharma Inc (EVP, Chief Commercial Officer · Feb 12, 2018 – Nov 19, 2021 · Past)
Director · Since at least Mar 4, 2025
Thomas W Beetham
Other companies: Viridian Therapeutics, Inc. (Chief Operating Officer · Since at least Oct 30, 2023); Kiniksa Pharmaceuticals International, plc (EVP & Chief Legal Officer · May 23, 2018 – Mar 20, 2021 · Past)
See Remarks · Jun 14, 2021 – Nov 30, 2022 · Past
Amy Ronneberg
Other companies: Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024)
Director · Jun 20, 2018 – Jun 28, 2022 · Past
Anne McGeorge
Other companies: The Oncology Institute, Inc. (Director · Since at least Nov 12, 2021)
Director · Since at least Jun 20, 2019
Blake Byers
Other companies: IonQ, Inc. (Director · Sep 30, 2021 – May 26, 2022 · Past)
Director · Jun 20, 2018 – Jun 5, 2020 · Past
Cindy Driscoll
Other companies: Climb Bio, Inc. (Senior Vice President, Finance · Since at least Jun 17, 2025)
See Remarks · Jun 20, 2018 – Oct 1, 2020 · Past
Edward Carr
Other companies: Abeona Therapeutics Inc. (Chief Financial Officer · Nov 9, 2018 – Oct 8, 2021 · Past)
Chief Accounting Officer · Since at least Sep 11, 2023
Kristen Stants
Other companies: Parabilis Medicines, Inc. (Chief People Officer · Since at least Nov 4, 2026)
Chief People Officer · Mar 2, 2020 – Nov 30, 2022 · Past
Simon Read
Other companies: Ra Pharmaceuticals Inc (Chief Scientific Officer · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least May 22, 2025
Zoran Zdraveski
Other companies: TScan Therapeutics, Inc. (Chief Legal and Strategy Officer and Secretary · Since at least Sep 7, 2021)
See Remarks · Jun 20, 2018 – Feb 11, 2021 · Past
Christina K IsacsonChief Business Officer · Jun 20, 2018 – Feb 10, 2020 · Past
David Roy WitzkeDirector · Jan 22, 2024 – Jan 22, 2024 · Past
David Wayne NicholsChief Technical Officer · Apr 19, 2021 – Aug 1, 2022 · Past
Jason GardnerSee Remarks, Director · Jun 20, 2018 – Nov 30, 2022 · Past
Jennifer Davis RuffHead of Investor Relations and Corporate Affairs · Since at least Nov 4, 2026
John C Davis JrSee Remarks · Jun 20, 2018 – Feb 11, 2021 · Past
Lisa OlsonSee Remarks · Sep 14, 2020 – Aug 1, 2022 · Past
Michael David GregoryDirector · Jan 22, 2024 – Jan 22, 2024 · Past
Michael P CookeChief Scientific Officer · Jun 20, 2018 – Dec 2, 2019 · Past
Ryan SavitzExecutive Vice President, Chief Financial Officer & Chief Business Officer · Since at least Sep 11, 2023
Simrat RandhawaExecutive Vice President, Head of R&D · Since at least Sep 11, 2023

Open People

Log in to ask 6ix AI your own questions about Dianthus Therapeutics, Inc.